Table 2.

Postoperative and post-adjuvant biomarker levels. Number of patients with relapse, without relapse, metastasectomy, and non-CRC-related death during follow-up.

		Postoperative	Post-Adjuvant
		0 Months	8 Months from Randomisation	No Relapse	Relapse	Metastasectomy	Non-CRC Death
		n = 147	n = 135	n = 81	n = 54	n = 23	n = 12
CEA	n	132	130	79	51	22	11
	Median (range) (µg/L)	1.9 (<1–305)	2.5 (<1–111)	2.3 (<1–7)	2.6 (<1–111)	2.3 (<1–15)	2.1 (<1–8)
	Elevated (>5 μg/L), n (%)	18 (14)	15 (12)	5 (6)	10 (20)	3 (14)	2 (18)
CA19-9	n	111	119	74	45	22	10
	Median (range) (kU/L)	6.0 (<5–2003)	6.0 (<5–902)	6.5 (<5–108)	<5 (<5–902)	<5 (<5–27)	7.0 (<5–27)
	Elevated (>26 kU/L), n (%)	12 (11)	13 (10)	8 (11)	5 (11)	1 (5)	1 (10)
IL-6	n	143	128	76	52	22	11
	Median (range) (pg/mL)	2.3 (0.4–36)	1.9 (0.2–25)	1.6 (0.2–10)	2.4 (0.7–25)	1.8 (0.7–25)	2.2 (1–10)
	Elevated (>4.5 pg/mL), n (%)	24 (17)	20 (16)	5 (7)	15 (29)	4 (18)	4 (36)
CRP	n	146	132	79	53	22	11
	Median (range) (mg/L)	<5 (<5–174)	<5 (<5–175)	<5 (<5–15)	<5 (<5–175)	<5 (<5–14)	<5 (4–15)
	Elevated (>10 mg/L), n (%)	17 (12)	10 (8)	4 (5)	6 (11)	2 (9)	2 (18)
YKL-40	n	144	131	78	53	23	11
	Median (range) (ng/mL)	64.5 (20–1524)	68.0 (20–1140)	63.5 (20–230)	89 (20–1140)	66 (20–175)	84 (34–203)
	Elevated (>70.7), n (%)	63 (44)	64 (49)	34 (44)	30 (57)	10 (43)	7 (64)